Table 1.
Characteristics of patients who continued or prematurely stopped ticagrelor
| Characteristics | Ticagrelor, all (n=227) | Ongoing ticagrelor (n=180) | Stopped ticagrelor (n=47) | P-value* |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Age, years | 62.2±12.1 | 62.1±12.5 | 67.4±11.4 | <0.01 |
| Age, >65 years | 98 (43.2) | 72 (40.0) | 26 (55.3) | NS |
| Male, n | 149 (65.6) | 124 (68.9) | 25 (53.1) | <0.05 |
| Body mass index, kg/m2 | 30.4±5.8 | 30.2±5.4 | 31.5±7.2 | NS |
| Hypertension | 117 (51.5) | 88 (48.9) | 29 (61.7) | NS |
| Diabetes | 69 (30.4) | 55 (30.6) | 14 (29.8) | NS |
| Dyslipidemia | 107 (47.1) | 84 (46.9) | 23 (48.9) | NS |
| Prior PCI | 42 (18.5) | 28 (15.6) | 14 (29.8) | <0.05 |
| Prior CABG | 20 (8.8) | 11 (6.1) | 9 (19.1) | <0.005 |
| Nonwhite | 46 (20) | 26 (14) | 20 (43) | <0.005 |
| From Region | 145 (63.9) | 110 (61.1) | 35 (74.5) | NS |
| Presentation | ||||
| STEMI | 104 (45.6) | 82 (45.6) | 22 (46.8) | NS |
| NSTEMI | 80 (35.2) | 62 (34.4) | 18 (38.3) | NS |
| Shock | 14 (6.2) | 8 (4.4) | 6 (12.2) | <0.005 |
| Off-/on-label use according to PLATO | ||||
| Did not meet inclusion | 44 (19.4) | 36 (20.0) | 8 (17.0) | NS |
| Met PLATO exclusion | 39 (17.2) | 29 (16.1) | 10 (21.3) | NS |
| Off-label use | 74 (32.4) | 60 (33.3) | 14 (29.8) | NS |
| Treatment | ||||
| Eventually required CABG | 23 (10.1) | 18 (10.0) | 5 (10.6) | NS |
| Medical therapy | 18 (7.9) | 11 (6.1) | 7 (14.9) | <0.05 |
| PCI | 209 (92.1) | 169 (93.9) | 40 (85.1) | <0.05 |
| Follow-up questionnaire within the first 4 weeks | ||||
| Dyspnea | 47 (20.7) | 29 (16.1) | 18 (38.3) | <0.005 |
Notes:
*
Compared with ticagrelor ongoing therapy group. Values are n (%) or mean ± standard deviation. From Region, within 1 hour driving distance to the PCI facility; nonwhite, self-identified as non-Caucasian. Off-label use for ticagrelor was defined as those who did not meet inclusion and/or who met exclusion criteria.
Abbreviations: NS, not significant; PCI, percutaneous coronary interventions; CABG, coronary artery bypass surgery; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PLATO, Study of Platelet Inhibition and Patient Outcomes.